177 related articles for article (PubMed ID: 35612599)
1. Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway.
Luo Z; Luo Y; Liang X; Lyu Q; Meng F; Chen X; Wang Y; Fang W; Li A; Zhou D
ACS Biomater Sci Eng; 2022 Jun; 8(6):2526-2536. PubMed ID: 35612599
[TBL] [Abstract][Full Text] [Related]
2. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
3. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
4. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
[No Abstract] [Full Text] [Related]
5. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
6. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
7. A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
Wang X; Wang Y; Gou S
Int J Biochem Cell Biol; 2023 Apr; 157():106395. PubMed ID: 36871936
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
9. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
10. A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance .
Liu Y; Wang D; Liu H; Liu L; Li S; Zhou Z; Lu L; Liu X; He L; He D; Yu CY; Wei H
J Med Chem; 2023 Mar; 66(6):4045-4058. PubMed ID: 36897884
[TBL] [Abstract][Full Text] [Related]
11. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
12. Fighting against drug-resistant tumors by the inhibition of γ-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.
Wang L; Liu Z; He S; He S; Wang Y
J Mater Chem B; 2021 Jun; 9(22):4587-4595. PubMed ID: 34059856
[TBL] [Abstract][Full Text] [Related]
13. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Barth MC; Häfner N; Runnebaum IB; Weigand W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982792
[TBL] [Abstract][Full Text] [Related]
15. Corrosion-Activated Chemotherapeutic Function of Nanoparticulate Platinum as a Cisplatin Resistance-Overcoming Prodrug with Limited Autophagy Induction.
Cheng HJ; Wu TH; Chien CT; Tu HW; Cha TS; Lin SY
Small; 2016 Nov; 12(44):6124-6133. PubMed ID: 27717137
[TBL] [Abstract][Full Text] [Related]
16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
17. A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug.
Li J; Lyv Z; Li Y; Liu H; Wang J; Zhan W; Chen H; Chen H; Li X
Biomaterials; 2015 May; 51():12-21. PubMed ID: 25770993
[TBL] [Abstract][Full Text] [Related]
18. Self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma.
Xiao X; Wang Y; Chen J; Qin P; Chen P; Zhou D; Pan Y
Biomaterials; 2022 Oct; 289():121793. PubMed ID: 36126545
[TBL] [Abstract][Full Text] [Related]
19. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
[TBL] [Abstract][Full Text] [Related]
20. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]